Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Casirivimab/imdevimab  COVID-19 treatment studies for Casirivimab/i..  C19 studies: Casirivimab/i..  Casirivimab/i..   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality -200% Improvement Relative Risk Mortality (b) 60% Progression 45% Progression (b) 50% c19early.org/r Suzuki et al. Casirivimab/i.. for COVID-19 EARLY Favors casirivimab/im.. Favors control

Real-world clinical outcomes of treatment with casirivimab-imdevimab among patients with mild-to-moderate coronavirus disease 2019 during the Delta variant pandemic

Suzuki et al., medRxiv, doi:10.1101/2021.12.19.21268078 (Preprint)
Suzuki et al., Real-world clinical outcomes of treatment with casirivimab-imdevimab among patients with mild-to-moderate.., medRxiv, doi:10.1101/2021.12.19.21268078 (Preprint)
Dec 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 949 patients in Japan, 314 treated with casirivimab/imdevimab showing significantly lower risk of deterioration with treatment.
Efficacy is variant dependent. In Vitro research suggests a lack of efficacy for omicron [Liu, Sheward, Tatham, VanBlargan].
risk of death, 200.0% higher, RR 3.00, p = 1.00, treatment 1 of 222 (0.5%), control 0 of 222 (0.0%), continuity correction due to zero event (with reciprocal of the contrasting arm), propensity score matching.
risk of death, 59.6% lower, RR 0.40, p = 0.67, treatment 1 of 314 (0.3%), control 5 of 635 (0.8%), NNT 213, unadjusted.
risk of progression, 45.2% lower, RR 0.55, p = 0.02, treatment 17 of 222 (7.7%), control 31 of 222 (14.0%), NNT 16, propensity score matching.
risk of progression, 49.9% lower, RR 0.50, p = 0.002, treatment 34 of 314 (10.8%), control 70 of 365 (19.2%), NNT 12, odds ratio converted to relative risk, multivariate.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Suzuki et al., 21 Dec 2021, retrospective, Japan, preprint, 49 authors, study period 24 July, 2021 - 30 September, 2021.
Contact: shibatay@fmu.ac.jp.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperCasirivimab/i..All
Real-world clinical outcomes of treatment with casirivimab-imdevimab among patients with mild-to-moderate coronavirus disease 2019 during the Delta variant pandemic
Yasuhito Suzuki, MD Yoko Shibata, Hiroyuki Minemura, Takefumi Nikaido, Yoshinori Tanino, Atsuro Fukuhara, Ryuzo Kanno, Hiroyuki Saito, Shuzo Suzuki, Taeko Ishii, Yayoi Inokoshi, Eiichiro Sando, Hirofumi Sakuma, Tatsuho Kobayashi, Hiroaki Kume, Masahiro Kamimoto, Hideko Aoki, Akira Takama, Takamichi Kamiyama, Masaru Nakayama, Kiyoshi Saito, Koichi Tanigawa, Masahiko Sato, Toshiyuki Kanbe, Norio Kanzaki, Teruhisa Azuma, Keiji Sakamoto, Yuichi Nakamura, Hiroshi Otani, Mitsuru Waragai, Shinsaku Maeda, Tokiya Ishida, Keishi Sugino, Yasuhiko Tsukada, Ryuki Yamada, Riko Sato, Takumi Omuna, Hikaru Tomita, Mikako Saito, Natsumi Watanabe, Mami Rikimaru, Takaya Kawamata, Takashi Umeda, Julia Morimoto, Ryuichi Togawa, Yuki Sato, Junpei Saito, Kenya Kanazawa, Ken Iseki
doi:10.1101/2021.12.19.21268078
This real-world retrospective study demonstrates the contribution of treatment with casirivimab-imdevimab to the prevention of deterioration in patients with mild-to-All rights reserved. No reuse allowed without permission. perpetuity.
References
Abu-Raddad, Chemaitelly, Butt, Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants, The New England journal of medicine
Austin, Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies, Pharmaceutical statistics
Baum, Fulton, Wloga, Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies, Science
Bernal, Andrews, Gower, Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant, The New England journal of medicine
Ganesh, Philpot, Bierle, Real-World Clinical Outcomes of Bamlanivimab and Casirivimab-Imdevimab Among High-Risk Patients With Mild to Moderate Coronavirus Disease 2019, The Journal of infectious diseases
Gottlieb, Nirula, Chen, Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial, Jama
Hu, Peng, Wang, Emerging SARS-CoV-2 variants reduce neutralization sensitivity to convalescent sera and monoclonal antibodies, Cellular & molecular immunology
Huang, Yang, Xu, Xu, Liu, Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19, Acta pharmacologica Sinica
Ito, Piantham, Nishiura, Predicted dominance of variant Delta of SARS-CoV-2 before Tokyo Olympic Games, Japan, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin
Korber, Fischer, Gnanakaran, Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus, Cell
Kumar, Banu, Sasikala, Effectiveness of REGEN-COV antibody cocktail against the B.1.617.2 (delta) variant of SARS-CoV-2: A cohort study, Journal of internal medicine
Planas, Veyer, Baidaliuk, Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization, Nature
Polack, Thomas, Kitchin, Safety and Efficacy of the BNT162b2 mRNA Covid-19
Razonable, Pawlowski, Horo, Casirivimab-Imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19, EClinicalMedicine
Shiba, Kawahara, Using Propensity Scores for Causal Inference: Pitfalls and Tips, Journal of epidemiology
Shibata, Minemura, Suzuki, Development and external validation of the DOAT and DOATS scores: simple decision support tools to identify disease progression among nonelderly patients with mild/moderate COVID-19
Taylor, Adams, Hufford, De La Torre, Winthrop et al., Neutralizing monoclonal antibodies for treatment of COVID-19, Nature reviews Immunology
The_Official_Website_Of_Fukushima_Prefecture, Confirmed cases of COVID-19 in Fukushima
The_Official_Website_Of_Fukushima_Prefecture, The variant of COVID-19 in Fukushima from
Uriu, Kimura, Shirakawa, Neutralization of the SARS-CoV-2 Mu Variant by Convalescent and Vaccine Serum, The New England journal of medicine
Vaccine, None, The New England journal of medicine
Verderese, Stepanova, Lam, Neutralizing Monoclonal Antibody Treatment Reduces Hospitalization for Mild and Moderate COVID-19: A Real-World Experience, Clinical infectious diseases
Wang, Nair, Liu, Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7, Nature
Weinreich, Sivapalasingam, Norton, REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19, The New England journal of medicine
Wilhelm, Toptan, Pallas, Antibody-Mediated Neutralization of Authentic SARS-CoV
Yamamoto, Wada, Ichikawa, Evaluation of Biomarkers of Severity in Patients with COVID-19 Infection, J Clin Med
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit